Veeva and Cvent Announce Management Integration
Veeva Systems and Cvent announced the companies will integrate Veeva CRM Events Management with Cvent’s meetings management software for end-to-end management of meetings and events, including congresses, conferences, and symposia.
Veeva will build and support a standard data connector to integrate the companies’ solutions, enabling event, attendee, and speaker information in Veeva CRM Events Management to flow to Cvent. Event planners will be able to manage event logistics, including venue sourcing, registration, travel booking, and on-site check-ins using Cvent, with these updates flowing back into Veeva CRM Events Management. This will allow field teams to view the same relevant details as the event planners in Cvent directly within Veeva CRM Events Management for improved visibility into HCP engagements.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
